Loading
Loading
Research Overview
Delta sleep-inducing peptide; proposed to modulate sleep architecture by interacting with somatostatin and CRF pathways, promoting slow-wave (delta) sleep and reducing ACTH/cortisol in stress models.
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring peptide that has been investigated in preclinical research for its potential involvement in sleep-related regulation and neuroendocrine signaling. Initially identified in association with sleep physiology, DSIP consists of a short chain of amino acids and has been studied primarily for its interactions within central nervous system pathways under controlled experimental conditions. Unlike many fully synthetic peptides, DSIP is considered endogenous in origin, though much of its function remains under active scientific exploration.
Across laboratory and animal-based models, DSIP has been examined for its potential influence on circadian-associated processes, stress responses, and hormonal regulation. Research has explored its interaction with systems involving neurotransmitters such as GABA and serotonin, as well as its possible relationship with sleep architecture and hypothalamic-pituitary activity. These investigations often focus on how DSIP may affect signaling pathways, receptor interactions, and regulatory feedback mechanisms tied to rest cycles and physiological balance.
In addition to its role in sleep-related studies, DSIP has been evaluated for its potential involvement in stress modulation and adaptive responses in experimental settings. Some preclinical findings suggest that it may influence endocrine activity, including pathways related to cortisol regulation, as well as cellular responses to environmental or induced stressors.
To enhance experimental reliability, DSIP has been synthesized and stabilized for laboratory use, allowing researchers to better examine its behavior under controlled conditions. All findings referenced are derived exclusively from non-clinical studies. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, dsip peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
DSIP Peptide research is most relevant to protocols examining:
Sleep architecture research
delta wave and slow-wave sleep promotion
HPA axis modulation and cortisol/ACTH regulation studies
Stress-induced sleep disruption investigations
Researchers studying peptide-based alternatives to conventional sleep agents
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Minutes to hours (in vivo)). Review data, confirm baseline recovery before any repeat protocol.
Delta sleep-inducing peptide; proposed to modulate sleep architecture by interacting with somatostatin and CRF pathways, promoting slow-wave (delta) sleep and reducing ACTH/cortisol in stress models.
| Parameter | Value |
|---|---|
| Dose range | 100–200 mcg/night |
| Schedule | Nightly |
| Route | Subcutaneous, Intranasal |
| Half-life | ~Minutes to hours (in vivo) |
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
